Reduced Glutathione ( DrugBank: Glutathione, Reduced glutathione )

2 diseases

告示番号	疾患名（ページ内リンク）	臨床試験数
6	パーキンソン病	3
299	嚢胞性線維症	4

6. パーキンソン病

臨床試験数 : 2,307 / 薬物数 : 2,007 - (DrugBank : 349) / 標的遺伝子数 : 188 - 標的パスウェイ数 : 199

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02424708 (ClinicalTrials.gov)	April 2015	15/4/2015	Phase IIb Study of Intranasal Glutathione in Parkinson's Disease	Phase IIb Study of Intranasal Glutathione in Parkinson's Disease	Parkinson's Disease	Drug: Reduced Glutathione 100mg;Drug: Reduced Glutathione 200mg;Drug: Placebo	Bastyr University	Michael J. Fox Foundation for Parkinson's Research	Completed	21 Years	N/A	Both	45	Phase 2	United States
2	NCT02324426 (ClinicalTrials.gov)	December 2014	4/12/2014	CNS Uptake of Intranasal Glutathione	Central Nervous System Uptake of Intranasal Glutathione in Parkinson's Disease	Parkinson's Disease	Drug: Reduced Glutathione	University of Washington	Michael J. Fox Foundation for Parkinson's Research	Completed	18 Years	N/A	Both	15	Phase 1	United States
3	NCT01398748 (ClinicalTrials.gov)	July 2012	19/7/2011	Intranasal Glutathione in Parkinson's Disease	A Phase 1 Study of Intranasal Reduced Glutathione in Parkinson's Disease	Parkinson's Disease (PD)	Drug: Intranasal glutathione - (in)GSH;Drug: Saline Intranasal Delivery	Bastyr University	National Center for Complementary and Integrative Health (NCCIH)	Completed	21 Years	100 Years	All	34	Phase 1	United States

First Previous1Next Last

299. 嚢胞性線維症

臨床試験数 : 1,695 / 薬物数 : 1,527 - (DrugBank : 268) / 標的遺伝子数 : 111 - 標的パスウェイ数 : 174

diseases per page:

Showing 1 to 4 of 4 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02029521 (ClinicalTrials.gov)	March 2011	30/12/2013	Supplementation of Oral Reduced Glutathione in Pediatric Cystic Fibrosis Patients	Supplementation of Oral Reduced Glutathione in Pediatric Cystic Fibrosis for Growth Failure	Cystic Fibrosis	Dietary Supplement: Oral reduced l-glutathione;Dietary Supplement: Placebo	Clark Bishop	NULL	Completed	18 Months	10 Years	All	47	N/A	Italy
2	NCT01450267 (ClinicalTrials.gov)	June 2010	30/9/2011	Inhaled Glutathione (GSH) Versus Placebo in Cystic Fibrosis	Randomized, Single Blind, Controlled Trial of Inhaled Glutathione Versus Placebo in Patients With Cy ...	Cystic Fibrosis	Drug: Inhaled Reduced Glutathione;Drug: Physiological solution	Serafino A. Marsico	Federico II University	Recruiting	6 Years	45 Years	Both	150	Phase 3	Italy
3	NCT00506688 (ClinicalTrials.gov)	July 2007	24/7/2007	Efficacy and Safety Study of Inhaled Glutathione in Cystic Fibrosis Patients	Randomized, Placebo-controlled, Double-blinded Study to Investigate the Efficacy and Safety of a 24- ...	Cystic Fibrosis	Drug: reduced glutathione sodium salt;Drug: 0.9% normal saline (control)	Mukoviszidose Institut gGmbH	Cystic Fibrosis Foundation Therapeutics	Completed	8 Years	N/A	Both	153	Phase 2	Germany
4	EUCTR2005-003870-88-DE (EUCTR)	20/10/2006	28/08/2006	Randomized, placebo-controlled, double-blind study to investigate the efficacy and safety of a 24-we ...	Randomized, placebo-controlled, double-blind study to investigate the efficacy and safety of a 24-we ...	Cystic fibrosis (CF) is the most common autosomal recessive lethal hereditary disorder in Caucasians ...	Product Name: GSH (Glutathione) Product Code: TAD 600 INN or Proposed INN: Glutathione Other descriptiv ...	Mukoviszidose Institut gGmbH i. G.	NULL	Not Recruiting			Female: yes Male: yes	160		Germany

First Previous1Next Last

先頭へ